mk-0616
merck
[]
this could be huge oral pcsk9i mk-0616:
mk-0616 demonstrated statistically significant dose-dependent placebo-adjusted reductions in ldl-c at week 8 of up to 60.9%. was well tolerated over 8 weeks of treatment &amp; an additional 8 weeks of follow up. #acc23
Non-interventional Cardiologist. Toledo. #Echo #cardiotwitter #RPVI #vascularUS #imagefirst tweets, retweets, comments arent medical advice.